Sjögren syndrome associated with multiple myeloma of the IgA κ-type

Modern Rheumatology

Volumn 10, Issue 2, 2000, Pages 110-113

  Akimoto, T ^a   Kobayashi, S ^a   Tamura, N ^a   Bando, H ^a   Ikeda, M ^a   Fujii, T ^a   Hirano, T ^a   Takasaki, Y ^a   Hashimoto, H ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gammopathy macroglobulinemia; Lymphoma; Multiple myeloma; Sj gren syndrome

Indexed keywords

EID: 51349125562     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/s101650050008     Document Type: Article

References (19)

1. Fox R. Clinical features, pathogenesis and treatment of Sjögren's syndrome. Curr Opin Ftheumatol 1996; 8: 438 – 45.
2. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888 – 92.
3. Zulman J, Jaffe R, Talal N. Evidence that the malignant lymphoma of Sjögren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med 1978; 299: 1215 – 20.
4. Moutsopoulos HM, Steinberg AD, Fauci AS, Lane HC, et al. High incidence of free monoclonal A. light chains in the sera of patients with Sjögren's syndrome. J Immunol 1983; 130: 2663 – 5.
5. Moutsopoulos HM, Costello NR, Drosos AA, Mavridis AK, et al. Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis 1985; 44: 109 – 12.
6. Sugai S, Konda S, Shirasaki Y, Murayama T, et al. Non-IgM mono-clonal gammopathy in patients with Sjögren's syndrome. Am J Med 1980; 689: 861 – 6.
7. Shearn KA, Moutsopoulos HM, Sawada S, Gak C, et al. Sjögren's syndrome with light chain myeloma. West J Med 1975; 123: 496 – 7.
8. Akashi Y, Yoshizawa N, Kubota T, Oshikawa Y, et al. Primary biliary cirrhosis complicated with Sjögren's syndrome and multiple myeloma. Nephron 1996; 73: 730 – 2.
9. Rodriguez-Cuartero A, Salas-Galan S. Sj 8gren's syndrome and multiple myeloma. Eur J Cancer 1997; 33: 167 – 8.
10. Casaril M, Venturini L, Pecci R, Bonazzi Z, et al. A case of parotidal myeloma in Sj8gren's syndrome. Haematologica 1987; 72: 167 – 70.
11. Keyle RA. “Benign” monoclonal gammopathy. JAMA 1984; 241: 1849 – 55.
12. Tsuchiya N, Sato M, Uesaka Y, Kurose N, et al. Lambert-Eaton myasthenic syndrome associated with Sjögren's syndrome and discoid lupus erythematosus. Scand J Ftheumatol 1993; 22: 302 – 84.
13. McCauliffe DP. Cutaneous diseases in adults associated with anti-Ro/SS-A autoantibody production. Lupus 1997; 6: 158 – 66.
14. Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996; 39: 1376 – 84.
15. Grewal IS, Flavell RA. A central role of CD40 ligand in the regu-lation of CD4+ T-cell responses. Immunol Today 1996; 17: 410 – 15.
16. Hilbelt DM, Shen M-Y, Rapp UR, Rudikoff S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci USA 1995; 92: 649 – 53.
17. Flescher E, Vela-Roch N, Nakabayashi T, Escalante A, et al. Abnormality of Oct-1 DNA binding in T cells from Sjögren's syndrome patients. Eur J Immunol 1996; 26: 2006 – 11.
18. Kroneld U, Halse A-K, Jonsson R, Bremen T, et al. Differential immunological aberration in patients with primary and secondary Sjögren's syndrome. Scand J Immunol 1997; 45: 698 – 705.
19. Ogawa N, Dang H, Kong Lanaya J-M, et al. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjögren's syndrome. Arthritis Rheum 1996; 39: 1875 – 85.